NF-κB transcription factors are aberrantly activated in most human cancers, including multiple myeloma (MM), where they drive oncogenesis, therapy resistance and malignant cell survival largely by upregulating genes that suppress cancer-cell apoptosis. The gene discussed is NFKB1; the disease is AL amyloidosis.